Most Recent
Cargill wins bid to call King & Wood Mallesons solicitor as a witness
A judge has granted Cargill Australia's request to call a King & Wood Mallesons solicitor that represented Viterra as a witness in the epic trial over the $420 million sale of Viterra's Joe White business to Cargill in 2013.
Viterra points finger at ex-employees in trial over $420M Joe White sale
Viterra is blaming several former employees for representations made about malt quality in the lead-up to the $420 million sale of its Joe White business to Cargill Australia in 2013.
Fitch class action can probe rosy ratings of Sigma Finance
The lead applicant in an investor class action against Fitch Ratings will get its hands on internal reports detailing why the agency assigned a Triple A rating to Sigma Finance Corporation ahead of its 2008 collapse, and whether it could have predicted the fall of the $27 billion investment fund. 
Fitch Ratings class can add fraud claims after finding hidden evidence
The firm running the class action against Fitch Ratings over SCDO products has been given the go ahead to add claims of fraud and deceit after lawyers allegedly unearthed a hidden mathematical table the agency used in assigning ratings to the toxic financial products.
Squire Patton Boggs lawyer says Fitch having a discovery ‘whinge’ in class action
Facing cross-examination over the law firm's bid to add fraud and deceit claims to a class action against Fitch Ratings, a Squire Patton Boggs lawyer exchanged fire with a barrister for the ratings agency, saying Fitch was having a regular "whinge" about discovery and "no" she would not take the comment back.
Norton Rose, ex-partner head to trial after mediation fails
A thorny dispute between Norton Rose Fulbright and former employment partner Thomas Martin will head to trial after the Federal Court heard Monday that "all attempts at mediation have failed".
GSK loses patent infringement appeal over slow-release Panadol
A full bench of the Federal Court has dismissed an appeal by drug giant GlaxoSmithKline in a patent infringement case it brought over planned generic versions of its sustained-release Panadol.